COMPASS Pathways reframes PTSD treatment after Lykos' MDMA setback, highlighting resilience-oriented care and the emerging role of psilocybin-assisted therapy

PTSD treatment is being reframed around resilience after regulatory and commercial setbacks for MDMA-assisted therapy, with COMPASS Pathways positioning psilocybin as a potentially more scalable and clinically durable alternative. The focus shifts from a single breakthrough narrative toward broader models of trauma care that combine symptom reduction with longer-term psychological flexibility and functional recovery. COMPASS Pathways is associated with psilocybin development rather than MDMA, so the comparison centers on how the field may respond after Lykos' difficulties. Resilience becomes a strategic and clinical lens for distinguishing psychedelic treatment approaches, especially around trial design, therapeutic support, and expectations about efficacy across diverse trauma populations. The wider implication is an industry pivot from hype-driven competition toward differentiation in mechanism, care model, and regulatory positioning. Psilocybin's role in PTSD remains investigational, but the discussion signals how companies may seek new narratives and clinical endpoints as psychedelic medicine moves deeper into mainstream scrutiny.